Telix Makes $2.35 Billion Bet on ITM to Build a Global Powerhouse in Cancer Radiopharmaceuticals
Telix Pharmaceuticals has agreed to merge with Germany’s ITM Isotope Technologies Munich in a transaction potentially worth $2.35 billion, a major expansion designed to strengthen Telix’s position in the rapidly growing market for radioactive medicines used to diagnose and treat cancer. The combination brings together two complementary businesses. Australia-based Telix develops radiopharmaceuticals for cancer imaging […]
